Tanios Bekaii-Saab, MD
Dr. Bekaii-Saab completed his undergraduate studies at McGill University and earned his MD at the American University of Beirut. His residency in internal medicine was at the Indiana University Medical Center, followed by fellowships in hematology/oncology and in clinical pharmacology at Tufts University-New England Medical Center.
Dr. Bekaii-Saab is Co-Leader of the Enterprise wide Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center and Professor at the Mayo Clinic College of Medicine and Science. He is actively involved in ASCO, AACR, and the American Society for Clinical Pharmacology and Therapeutics. Dr. Bekaii-Saab is co-leader for the hepato-biliary cancer committee for the Alliance cooperative group and the Alliance representative for the NCI hepato-biliary national cancer task force. He is also the SWOG representative for the NCI pancreatic cancer task force and senior executive leader for solid tumor research and GI cancer committee co-lead for the Mayo clinic- sponsored ACCRU network. An active peer reviewer for more than 50 prestigious journals, Dr. Bekaii-Saab has authored more than 350 peer-reviewed publications, abstracts in prominent journals, and book chapters.
Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research, molecular targeted and immune therapies. He is the principal investigator on numerous clinical trials supported by government, industry and NCCN. He has been awarded the prestigious NCI clinical investigator team leadership award and the ASCO leadership program development award.